DDInter783 DDInter899
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fosphenytoin {u} (Compound) resembles {v} (Compound) Modafinil
Fosphenytoin {u} (Compound) resembles {v} (Compound) Methylphenobarbital
Fosphenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
Fosphenytoin {u} (Compound) binds {v} (Gene) CYP2C9
Fosphenytoin {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Fosphenytoin {u} (Compound) causes {v} (Side Effect) Encephalopathy
Fosphenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Fosphenytoin (Compound) resembles Modafinil (Compound)
Fosphenytoin (Compound) resembles Methylphenobarbital (Compound)
Fosphenytoin (Compound) treats epilepsy syndrome (Disease)
Fosphenytoin (Compound) binds CYP2C9 (Gene)
Fosphenytoin (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Fosphenytoin (Compound) causes Encephalopathy (Side Effect)
Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Fosphenytoin may lead to a major life threatening interaction when taken with Apremilast